Phase 1 Study of XAF5 Gel Applied to Skin of Healthy Volunteers
Launched by TOPOKINE THERAPEUTICS, INC. · Nov 6, 2012
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy volunteers
- • Must understand and provide informed consent
- • Skin upon which a reaction would be visible
- • Body weight \>= 70 kg
- Exclusion Criteria:
- • Any active skin disease
- • History of skin hypersensitivity
- • Clinically significant abnormality on physical exam, ECG, or laboratory tests
- • Positive test for HIV, Hepatitis B, or Hepatitis C
Trial Officials
Michael S. Singer, MD, PhD
Study Director
Topokine Therapeutics
About Topokine Therapeutics, Inc.
Topokine Therapeutics, Inc. is a pioneering biotechnology company focused on developing innovative therapeutics to address unmet medical needs in dermatology and aesthetic medicine. With a commitment to advancing patient care, Topokine leverages its proprietary drug delivery technologies to create targeted treatments for conditions such as hyperhidrosis and other skin disorders. The company is dedicated to conducting robust clinical trials that validate the efficacy and safety of its products, aiming to enhance the quality of life for patients while driving advancements in the field of dermatological therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
